Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company, announced that its chief business officer, George Tziras, will present at the Jefferies Global Healthcare Conference, scheduled for November 17–20, 2025, in London. This presentation provides an opportunity for Cybin to showcase its proprietary drug discovery platforms and delivery systems aimed at transforming mental healthcare. The full press release is available at https://ibn.fm/bb3sl.
Cybin is focused on addressing the large unmet need for individuals suffering from mental health conditions through innovative next-generation treatment options. The company is currently developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for the adjunctive treatment of major depressive disorder (MDD). CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), highlighting its potential to offer effective and durable results for patients. Additionally, Cybin is advancing CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder (GAD). The company also maintains a research pipeline of investigational 5-HT-receptor focused compounds.
The presentation at the Jefferies Global Healthcare Conference is significant as it provides a platform for Cybin to engage with the investment community and discuss its clinical progress and strategic direction. For investors and stakeholders, this event offers insights into the company's milestones, including the Phase 3 development of CYB003 and the Phase 2 study of CYB004. The conference is a key venue for healthcare and biotech companies to highlight their innovations and attract potential partnerships or funding.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland. With promising class-leading data, the company is working to change the mental health treatment landscape. The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.
This announcement underscores Cybin's commitment to advancing mental health treatments and its active role in the global healthcare investment community. The Jefferies conference is an important venue for biotech companies to present their progress, and Cybin’s participation reflects its growing prominence in the neuropsychiatry sector.
